Thought Leadership
Publications
2024 Cell and Gene Therapy Report: Advancing the Future of Medicine
Our 2024 Cell and Gene Therapy Report reviews where CGT stands today and its future trajectory, while exploring pain points and barriers to broader adoption and access. The report shares perspectives from experts across the industry, data from a survey of 124 oncologists about their use of CGT products, and a first-of-its-kind map illustrating the “CGT deserts” across the US.
Expanding Access to Cell and Gene Therapies Through Innovative Pathways and Policy Reform: Asembia 2025
In this First Report Managed Care interview from Asembia 2025, Joe DePinto shares how early planning and specialty pharmacy partnerships can help unlock broader access to CGTs.
The Promise of Cell and Gene Therapies: Overcoming Commercialization Challenges Through Collaboration and Innovation
In First Report Managed Care, Joe DePinto breaks down key barriers to CGT access and outlines strategies for overcoming these barriers.
Are Cell and Gene Therapies Overpromised or Facing Growing Pains | Asembia’s AXS25 Summit
At Asembia 2025, Joe DePinto spoke with Managed Healthcare Executive about what it takes for CGTs to succeed, from clearly defining value and identifying the right patients to aligning with payer expectations.
Cell and Gene Therapies Hold Promise, but Access Barriers Persist
In The American Journal of Managed Care, Joe DePinto shares key insights from InspiroGene’s 2024 CGT Report and discusses how to bridge the gap between CGT innovation and reality.
The Real-World Challenges of Cell and Gene Therapy in Oncology
In this interview with Targeted Oncology, Joe DePinto shares insights from InspiroGene’s 2024 CGT Report, including how geographic disparities and socioeconomic barriers impact patient access.
Is Community the Next Frontier for Cell and Gene Therapy?
In Pharmaceutical Executive, Elias Pittos and Robert Richards explore how community treatment centers and academic medical centers can work together to expand CGT access.
ASCO 2025: Key Takeaways from the American Society of Clinical Oncology Annual Meeting
Elias Pittos shares promising CGT developments from ASCO 2025, including advances in therapies for solid tumors and blood cancers.
PART 3: Commercializing Your First CGT Product: Value Chain Planning
In part 3 of this series, Joe DePinto provides advice on developing a value chain strategy that is purpose-built for CGT.
PART 2: Commercializing Your First Cell or Gene Therapy (CGT): Developing Your Market Access Strategy
CGT commercial success takes more than innovation – it takes strategy. In part 2 of this series, Joe DePinto outlines the components of an effective market access plan.
PART 1: Commercializing Your First Cell or Gene Therapy (CGT): Five Best Practices for Planning
In part 1 of this series, Joe DePinto shares 5 must-know best practices for preparing for CGT commercial success.
Will the CMS CGT Model Support Patient Access to Sickle Cell Disease CGTs?
In CGT Live, Joe DePinto, Erin Lopata, and Phil Cyr explore how the CMS CGT Access Model could expand patient access to gene therapies for sickle cell disease, and examine strategies for overcoming potential barriers.
PART 2: Getting the System Ready: Enabling Investment in Community Hospitals to Improve Patient Access to Cell and Gene Therapies
Part 2 of this Cell & Gene series explores the infrastructure, investments, and partnerships needed to expand CGTs into community settings.
PART 1: Mobilizing Community Hospitals to Improve Access to Cell and Gene Therapy
In part 1 of this article series in Cell & Gene, experts Sanjay Srivastava, Rahul Mirchandani, and Joe DePinto discuss how expanding CGT delivery into community hospitals can address access barriers.
Presentations
Transforming Patient Care by Meeting the Challenges of CGT
At ARM’s 2024 Cell & Gene Meeting on the Mesa, Joe DePinto shared how InspiroGene is addressing key challenges in patient access, scalability, and commercialization to help expand the reach and impact of CGTs.
Podcasts
InspiroGene: Revolutionizing the Cell and Gene Therapy Landscape With Joe DePinto, MBA, and Waqas Haque, MD, MPH
In this episode of Oncology Data Advisor, Joe DePinto and host Waqas Haque discuss the growing demand for CGT commercialization and InspiroGene’s integrated approach to expanding CGT access.
Expanding Access to Cell and Gene Therapies With McKesson’s Joe DePinto
On this episode of Transforming Biopharma by ZS, Maria Whitman speaks with Joe DePinto about the evolving CGT landscape and how strategic support across the treatment journey can improve outcomes for patients.
Cell and Gene Therapies: The Logistics
On this episode of Healthcare Unfiltered, Joe DePinto, Head of Cell, Gene & Advanced Therapies at McKesson, joins host Chadi Nabhan to discuss patient access barriers to CGTs and how to scale these therapies for larger populations.
Joe DePinto: Bridging Growth and Accessibility Within CGTs
On the Ori Spotlight Podcast, Joe DePinto joins host Jason C. Foster to discuss how strategic partnerships and digital innovation are transforming CGT manufacturing, supply chains, and patient access.
